[go: up one dir, main page]

MX2016013457A - Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. - Google Patents

Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.

Info

Publication number
MX2016013457A
MX2016013457A MX2016013457A MX2016013457A MX2016013457A MX 2016013457 A MX2016013457 A MX 2016013457A MX 2016013457 A MX2016013457 A MX 2016013457A MX 2016013457 A MX2016013457 A MX 2016013457A MX 2016013457 A MX2016013457 A MX 2016013457A
Authority
MX
Mexico
Prior art keywords
same
mdm2
therapeutic methods
mdm2 inhibitors
inhibitors
Prior art date
Application number
MX2016013457A
Other languages
English (en)
Other versions
MX373045B (es
Inventor
Wang Shaomeng
Aguilar Angelo
Lu Jianfeng
Mceachern Donna
LUI Lui
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2016013457A publication Critical patent/MX2016013457A/es
Publication of MX373045B publication Critical patent/MX373045B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan inhibidores de MDM2 y proteínas relacionadas a MDM2 y composiciones que contienen los mismos. También se divulgan métodos para el uso de inhibídores de MDM2 en el tratamiento de enfermedades y afecciones en donde la inhibición de una interacción entre p53 y MDM2 proporciona un beneficio, como en el caso del cáncer.
MX2016013457A 2014-04-17 2015-04-16 Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. MX373045B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980747P 2014-04-17 2014-04-17
PCT/US2015/026098 WO2015161032A1 (en) 2014-04-17 2015-04-16 Mdm2 inhibitors and therapeutic methods using the same

Publications (2)

Publication Number Publication Date
MX2016013457A true MX2016013457A (es) 2017-05-04
MX373045B MX373045B (es) 2020-05-26

Family

ID=54321424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013457A MX373045B (es) 2014-04-17 2015-04-16 Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2020003939A MX2020003939A (es) 2014-04-17 2016-10-13 Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003939A MX2020003939A (es) 2014-04-17 2016-10-13 Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.

Country Status (12)

Country Link
US (1) US9745314B2 (es)
EP (1) EP3131544B1 (es)
JP (2) JP6694827B2 (es)
KR (2) KR102599945B1 (es)
CN (2) CN111718354A (es)
AU (1) AU2015247646B2 (es)
CA (1) CA2945527C (es)
ES (1) ES2712973T3 (es)
IL (2) IL248211B (es)
MX (2) MX373045B (es)
SG (2) SG11201608667SA (es)
WO (1) WO2015161032A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2015161032A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
KR20170042779A (ko) 2014-08-21 2017-04-19 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 신규 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
US9962380B2 (en) * 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
PL3359542T3 (pl) 2015-10-09 2021-09-20 Boehringer Ingelheim International Gmbh Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
CN109415336B (zh) * 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US11339171B2 (en) * 2017-12-29 2022-05-24 Gan & Lee Pharmaceuticals MDM2 inhibitors
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
CN110776507B (zh) 2018-07-31 2020-12-18 苏州亚盛药业有限公司 Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
UA126098C2 (uk) * 2018-07-31 2022-08-10 Есентейдж Фарма (Сучжоу) Ко., Лтд. КОМБІНОВАНИЙ ПРОДУКТ НА ОСНОВІ ІНГІБІТОРА Bcl-2 ТА ІНГІБІТОРА MDM2 ТА ЙОГО ЗАСТОСУВАННЯ В ПОПЕРЕДЖЕННІ ТА/АБО ЛІКУВАННІ ЗАХВОРЮВАНЬ
EA202091963A1 (ru) 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГИЧЕСКИЙ ПРОТИВООПУХОЛЕВЫЙ ЭФФЕКТ ИНГИБИТОРА Bcl-2 В СОЧЕТАНИИ С РИТУКСИМАБОМ И/ИЛИ БЕНДАМУСТИНОМ ИЛИ ИНГИБИТОРА Bcl-2 В СОЧЕТАНИИ С CHOP
AU2019316865A1 (en) * 2018-08-08 2020-12-17 Ascentage Pharma (Suzhou) Co., Ltd. Combination of immunotherapies with MDM2 inhibitors
CN111214468B (zh) * 2018-11-23 2021-02-05 苏州亚盛药业有限公司 新型药物组合物及其用途
KR20210003178A (ko) * 2018-12-14 2021-01-11 어센테지 파마 (쑤저우) 컴퍼니 리미티드 골관절염을 치료하기 위한 화합물
TWI772753B (zh) * 2019-02-24 2022-08-01 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的治療方法和生物標記物
TWI750728B (zh) * 2019-07-11 2021-12-21 大陸商蘇州亞盛藥業有限公司 2-吲哚啉螺環酮類化合物的製備方法及其中間體
EP3999056A4 (en) * 2019-07-19 2023-10-25 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN118812542A (zh) * 2020-01-23 2024-10-22 苏州亚盛药业有限公司 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
US12528785B2 (en) * 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
CN113521064A (zh) * 2020-04-14 2021-10-22 苏州亚盛药业有限公司 Mdm2抑制剂的新用途
CN113801120B (zh) * 2020-06-15 2024-03-22 苏州亚盛药业有限公司 Mdm2抑制剂的微悬浮液以及治疗应用
TW202214248A (zh) 2020-08-27 2022-04-16 日商大塚製藥股份有限公司 使用ｍｄｍ２拮抗劑的癌症療法之生物標記
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022170108A1 (en) * 2021-02-04 2022-08-11 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof in prevention of radiation injury
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023011488A1 (zh) 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023134707A1 (en) * 2022-01-11 2023-07-20 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating aml-mrc and mds
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
ES2538714T3 (es) 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
CN101400680B (zh) * 2006-03-13 2012-04-25 霍夫曼-拉罗奇有限公司 螺吲哚满酮衍生物
EP1996591B1 (en) * 2006-03-13 2011-01-12 F. Hoffmann-La Roche AG Spiroindolinone derivatives
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
EP2063887B1 (en) * 2006-08-30 2013-05-29 The Regents of the University of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
US20080188506A1 (en) * 2007-02-07 2008-08-07 Qingjie Ding Spiroindolinone derivatives
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MX2011002976A (es) 2008-09-18 2011-04-11 Hoffmann La Roche Pirrolidina-2-carboxamidas sustituidas.
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
AU2010319595B2 (en) 2009-11-12 2015-09-17 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
EP2563360A4 (en) * 2010-04-09 2015-12-16 Univ Michigan BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN DISEASE TREATMENT
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
CA2829188C (en) * 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
ES2624808T3 (es) * 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
KR20220136454A (ko) * 2013-09-04 2022-10-07 다이이찌 산쿄 가부시키가이샤 스피로옥시인돌 유도체의 제조 방법
WO2015161032A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same

Also Published As

Publication number Publication date
ES2712973T3 (es) 2019-05-17
IL248211A0 (en) 2016-11-30
WO2015161032A1 (en) 2015-10-22
CN111718354A (zh) 2020-09-29
CA2945527C (en) 2022-05-17
KR102599945B1 (ko) 2023-11-09
US9745314B2 (en) 2017-08-29
CA2945527A1 (en) 2015-10-22
US20150299211A1 (en) 2015-10-22
IL269462B (en) 2021-05-31
KR20160136450A (ko) 2016-11-29
KR102389552B1 (ko) 2022-04-22
AU2015247646A1 (en) 2016-10-27
NZ724963A (en) 2021-10-29
IL248211B (en) 2019-10-31
EP3131544B1 (en) 2018-12-12
JP2020100662A (ja) 2020-07-02
JP6909323B2 (ja) 2021-07-28
JP6694827B2 (ja) 2020-05-20
SG10201913742TA (en) 2020-03-30
CN106794171A (zh) 2017-05-31
MX373045B (es) 2020-05-26
JP2017511360A (ja) 2017-04-20
SG11201608667SA (en) 2016-11-29
EP3131544A4 (en) 2017-08-30
IL269462A (en) 2019-11-28
MX2020003939A (es) 2020-08-13
AU2015247646B2 (en) 2019-06-06
EP3131544A1 (en) 2017-02-22
KR20220054697A (ko) 2022-05-03
CN106794171B (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
MX2017012553A (es) Compuestos espirociclicos.
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.

Legal Events

Date Code Title Description
FG Grant or registration